Added therapeutic benefit and drug licensing

Nature Reviews Drug Discovery

3 September 2019 - One aspect of the ongoing debate about drug pricing is the added therapeutic benefit of new drugs compared with existing — and potentially cheaper — therapies. 

Here, we discuss the merits and pitfalls of proposals that are being discussed with regard to the role of regulatory agencies in establishing added therapeutic benefit.

Read Nature Reviews Drug Discovery comment

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , Europe , Regulation